Loading stock data…
Bio-Techne Corporation (TECH)
$71.00+0.30 (+0.42%)
Market ClosedLast close Jun 26
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bio-Techne Corporation in the Healthcare sector is trading at $71.00 with a market capitalization of $8.8B. Wall Street consensus targets $67.92 (13 analysts), implying a -4.3% move over the next 12 months. The stock is currently near its 52-week high of $72.16, remaining 23.4% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $311.42M↑ | $295.88M↑ | $286.56M↓ | $316.96M↑ | $316.18M |
| Gross Profit | $208.29M↑ | $191.28M↑ | $188.11M↓ | $198.81M↓ | $214.56M |
| Operating Income | $75.50M↑ | $54.46M↑ | $47.66M↓ | $116.69M↑ | $38.71M |
| Net Income | $51.05M↑ | $38.01M↓ | $38.19M↑ | -$17.68M↓ | $22.59M |
Peer Comparison
JNJUNHPFE
Fundamentals
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.76B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.34%
ROE
Average efficiency. Growth may require heavy reinvestment.
5.25%
Volume
Today's trading volume
12.26M
Recent News
The $11 Billion Reason TECH Stock Is Up Today
Bio-Techne stock rallies as Merck announces an agreement to acquire it for $73 per share. But is there any further upside left in TECH shares?
Merck KGaA to acquire Bio-Techne in $11.3 billion deal
The deal, Merck's largest since its Sigma-Aldrich buyout, expands its presence in proteins, spatial biology, and cell and gene therapy
Company News for Jun 26, 2026
Companies in The News Are: BB, MKC, META, TECH, MKKGY
Bio-Techne (TECH) Agrees To $11.5 Billion Merck KGaA Buyout
Merck KGaA has agreed to acquire Bio-Techne (NasdaqGS:TECH) for $11.5b in an all cash deal. Bio-Techne's board has unanimously approved the transaction, which is now subject to regulatory review. The companies highlight expected synergies and accretion to Merck KGaA’s earnings following completion. For investors tracking Bio-Techne, the agreed $11.5b acquisition by Merck KGaA lands after a sharp move in the stock, with NasdaqGS:TECH up 22% over the past week and 47% over the past month. The...
Germany’s Merck Pumps Up Life Sciences Biz with $11.3B Bio-Techne Deal
Merck KGaA's agreement to buy Bio-Techne for $11.3 billion strengthens its hold in life sciences, especially drug discovery and gene therapy.